Status:
WITHDRAWN
The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion
Lead Sponsor:
Pennington Biomedical Research Center
Collaborating Sponsors:
Quest Nutrition LLC
Conditions:
Obesity
Cardiovascular Disease
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Saturated fat leading to elevated low density lipoprotein (LDL) cholesterol is considered a cardiovascular risk factor. The properties associated with α- cyclodextrin, allow it to selectively reduce s...
Detailed Description
Alpha-cyclodextrin which functions as a soluble dietary fiber, has been shown to a form a stable emulsion with dietary fat in the ratio of 1:9, with a higher affinity for saturated fat compared to uns...
Eligibility Criteria
Inclusion
- BMI between 20 and 30 kg/m2 inclusive
- Weight ≥ 65 kg for females, and ≥ 55 kg for males
Exclusion
- Pregnant or nursing.
- Diabetes Mellitus
- Any medication to reduce lipids
- History of gastrointestinal surgery, except for cholecystectomy or appendectomy
- History of malabsorption
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01910558
Start Date
October 1 2013
End Date
October 1 2013
Last Update
April 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808